首页> 外文期刊>Drug metabolism and drug interactions >In silico pharmacology for a multidisciplinary drug discovery process.
【24h】

In silico pharmacology for a multidisciplinary drug discovery process.

机译:用于多种学科药物发现过程的计算机电子药理学。

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract The process of bringing new and innovative drugs, from conception and synthesis through to approval on the market can take the pharmaceutical industry 8-15 years and cost approximately $1.8 billion. Two key technologies are improving the hit-to-drug timeline: high-throughput screening (HTS) and rational drug design. In the latter case, starting from some known ligand-based or target-based information, a lead structure will be rationally designed to be tested in vitro or in vivo. Computational methods are part of many drug discovery programs, including the assessment of ADME (absorption-distribution-metabolism-excretion) and toxicity (ADMET) properties of compounds at the early stages of discovery/development with impressive results. The aim of this paper is to review, in a simple way, some of the most popular strategies used by modelers and some successful applications on computational chemistry to raise awareness of its importance and potential for an actual multidisciplinary drug discovery process.
机译:摘要从概念,合成到批准上市的新药和创新药物的生产过程可能需要8-15年的时间,制药行业的成本约为18亿美元。两项关键技术正在改善“从药物到药物”的时间表:高通量筛选(HTS)和合理的药物设计。在后一种情况下,将从一些已知的基于配体或目标的信息开始,合理设计先导结构以进行体外或体内测试。计算方法是许多药物发现计划的一部分,包括在发现/开发的早期阶段对化合物的ADME(吸收-分布-代谢-排泄)和毒性(ADMET)性质进行评估,结果令人印象深刻。本文的目的是以简单的方式回顾建模者使用的一些最流行的策略,以及在计算化学上的一些成功应用,以提高人们对其重要性的认识以及在实际的多学科药物发现过程中的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号